172 Preclinical profile of ABP309, a potent 2nd generation VEGF receptor tyrosine kinase inhibitor belonging to the class of aminonicotinamides

Autor:	R. Cozens, G. Bold, P.W. Manley, C. Schnell, Josef Brueggen, J. Mestan, J.M. Wood
Rok vydání:	2004
Předmět:	Cancer Research biology AXL receptor tyrosine kinase medicine.drug_class business.industry Tropomyosin receptor kinase C Receptor tyrosine kinase Tyrosine-kinase inhibitor Oncology ROR1 biology.protein medicine Cancer research business Tyrosine kinase Platelet-derived growth factor receptor Proto-oncogene tyrosine-protein kinase Src
Zdroj:	European Journal of Cancer Supplements. 2:54-55
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(04)80180-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2f3276d9e280a046b95db62d9f122d05 https://doi.org/10.1016/s1359-6349(04)80180-0 Zobrazit plný text záznamu Full Text from ScienceDirect